BRCC is part of a national exclusive group of centers where cancer patients are approved to enroll on Radiation Therapy Oncology Group (RTOG) protocols. Our collaboration through the RTOG brings us in communication with nationally recognized experts at major academic cancer centers. This helps Dr. Murshed to remain abreast of the most upto-date treatments for his patients. Dr. Murshed is an active participant in national RTOG clincial trials which enables his patients to receive the most upto-date and innovative treatment possible in a community setting in Panama City, FL.
To know more about RTOG please follow the link: RTOG Homepage
Clinical Trials Available at Bay Regional Cancer Center
Lung
RTOG 0117; Phase I/II dose intensification study using 2 dimensional conformal radiation therapy and concurrent chemoradiation for patients with inoperable, non-small cell lung cancer.
RTOG 0212; A phase II/III randomized trial of two dose schedules for delivering prophylactic cranial irradiation for patients with limited disease small cell lung cancer.
RTOG 0214; A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer.
RTOG 0320; A phase III trial comparing whole brain radiation and stereotactic radiosurgery alone vs. Temozolomide or Gefitinib in patients with non-small cell lung cancer and 1-3 brain metastasis (Gefitinib changed to Erlotinib 5-05)
Breast
RTOG 0413/NSABP B-39; a ranomized Phase III study of conventional whole breast irradiation (WBI) versus partial breast (PBI) for women with stage 0, I, or II breast cancer.
Gynecological
RTOG 0418; A phase II study of IMRT to the Pelvis +/- Chemotherapy for post op patient with Endometrial or Cervical Cancer. Endometrial arm closed.
Genito-urinary
RTOG 0521; A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by chemotherapy with Docetaxel and Prednisone for localized, high-risk prostate cancer.
RTOG 0126; A phase III randomized study of high dose 3DCRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer.
RTOG 0415; A phase III randomized study of hypofractionated 3DCRT/IMRT versus conventionally fractionated 3DCRT/IMRT in patients with favorable risk prostate cancer.
Head and Neck
RTOG 0522; A randomized phase III trial of concurrent accelerated radiation and Cisplatin vs. concurrent accelerated radiation, Cisplatin and Cetuximab (C225) [followed by surgery for selected patients] for stage II and IV head and neck carcinomas.
Brain
RTOG 0525; A phase II trial comparing conventional adjuvant Temozolomide with dose intensive Temozolomide in patients with newly diagnosed Glioblastoma.
Gastrointestinal
RTOG 0529; A phase II evaluation of dose painted IMRT in combination with 5-Fluorouracil and Mitomycin C for reduction of acute morbidity in carcinoma of the anal canal.